1. EldeNC, ChildSJ, EickbushMT, KitzmanJO, RogersKS, et al. (2012) Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell 150: 831–841.
2. BowieAG, UnterholznerL (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8: 911–922.
3. MedzhitovR (2007) Recognition of microorganisms and activation of the immune response. Nature 449: 819–826.
4. PichlmairA, Reis e SousaC (2007) Innate recognition of viruses. Immunity 27: 370–383.
5. PoltorakA, HeX, SmirnovaI, LiuMY, Van HuffelC, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085–2088.
6. CoorayS, BaharMW, AbresciaNG, McVeyCE, BartlettNW, et al. (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88: 1656–1666.
7. DiPernaG, StackJ, BowieAG, BoydA, KotwalG, et al. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279: 36570–36578.
8. BowieA, Kiss-TothE, SymonsJA, SmithGL, DowerSK, et al. (2000) A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 97: 10162–10167.
9. HarteMT, HagaIR, MaloneyG, GrayP, ReadingPC, et al. (2003) The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197: 343–351.
10. StackJ, HagaIR, SchroderM, BartlettNW, MaloneyG, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007–1018.
11. ChenRA, RyzhakovG, CoorayS, RandowF, SmithGL (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4: e22.
12. GrahamSC, BaharMW, CoorayS, ChenRA, WhalenDM, et al. (2008) Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4: e1000128.
13. SchroderM, BaranM, BowieAG (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. Embo J 27: 2147–2157.
14. GedeyR, JinXL, HinthongO, ShislerJL (2006) Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80: 8676–8685.
15. ShislerJL, JinXL (2004) The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 78: 3553–3560.
16. ValentineR, SmithGL (2010) Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J Gen Virol 91: 2221–2229.
17. EmberSW, RenH, FergusonBJ, SmithGL (2012) Vaccinia virus protein C4 inhibits NF-kappaB activation and promotes virus virulence. J Gen Virol 93: 2098–2108.
18. MansurDS, Maluquer de MotesC, UnterholznerL, SumnerRP, FergusonBJ, et al. (2013) Poxvirus targeting of E3 ligase beta-TrCP by molecular mimicry: A mechanism to inhibit NF-kappa B activation and promote immune evasion and virulence. PLoS Pathogens 9: doi 10.1371journal.ppat.1003183/journal.ppat.1003183
19. UnterholznerL, SumnerRP, BaranM, RenH, MansurDS, et al. (2011) Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7: e1002247.
20. FergusonBJ, BenfieldCT, RenH, LeeVH, FrazerGL, et al. (2013) Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol 94: 2070–81.
21. KettleS, AlcamiA, KhannaA, EhretR, JassoyC, et al. (1997) Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol 78: 677–685.
22. FergusonBJ, MansurDS, PetersNE, RenH, SmithGL (2012) DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. eLife 1: e00047.
23. CollisSJ, DeWeeseTL, JeggoPA, ParkerAR (2005) The life and death of DNA-PK. Oncogene 24: 949–961.
24. Rivera-CalzadaA, SpagnoloL, PearlLH, LlorcaO (2007) Structural model of full-length human Ku70-Ku80 heterodimer and its recognition of DNA and DNA-PKcs. EMBO Rep 8: 56–62.
25. SpagnoloL, Rivera-CalzadaA, PearlLH, LlorcaO (2006) Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 22: 511–519.
26. IshiiKJ, CobanC, KatoH, TakahashiK, ToriiY, et al. (2006) A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 7: 40–48.
27. StetsonDB, MedzhitovR (2006) Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24: 93–103.
28. TakaokaA, WangZ, ChoiMK, YanaiH, NegishiH, et al. (2007) DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448: 501–505.
29. RobertsTL, IdrisA, DunnJA, KellyGM, BurntonCM, et al. (2009) HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323: 1057–1060.
30. HornungV, AblasserA, Charrel-DennisM, BauernfeindF, HorvathG, et al. (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514–518.
31. BurckstummerT, BaumannC, BlumlS, DixitE, DurnbergerG, et al. (2009) An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 10: 266–272.
32. Fernandes-AlnemriT, YuJW, DattaP, WuJ, AlnemriES (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458: 509–513.
33. AblasserA, BauernfeindF, HartmannG, LatzE, FitzgeraldKA, et al. (2009) RIG-I-dependent sensing of poly(dA∶dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 10: 1065–1072.
34. ChiuYH, MacmillanJB, ChenZJ (2009) RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138: 576–591.
35. YangP, AnH, LiuX, WenM, ZhengY, et al. (2010) The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 11: 487–494.
36. KimT, PazhoorS, BaoM, ZhangZ, HanabuchiS, et al. (2010) Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 107: 15181–15186.
37. UnterholznerL, KeatingSE, BaranM, HoranKA, JensenSB, et al. (2010) IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 11: 997–1004.
38. ZhangZ, YuanB, BaoM, LuN, KimT, et al. (2011) The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 12: 959–965.
39. KondoT, KobayashiJ, SaitohT, MaruyamaK, IshiiKJ, et al. (2013) DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 110: 2969–2974.
40. SunL, WuJ, DuF, ChenX, ChenZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786–791.
41. WiebeMS, TraktmanP (2007) Poxviral B1 kinase overcomes barrier to autointegration factor, a host defense against virus replication. Cell Host Microbe 1: 187–197.
42. BurdetteDL, VanceRE (2012) STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 14: 19–26.
43. RathinamVA, JiangZ, WaggonerSN, SharmaS, ColeLE, et al. (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11: 395–402.
44. Fernandes-AlnemriT, YuJW, JulianaC, SolorzanoL, KangS, et al. (2010) The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 11: 385–393.
45. BurdetteDL, MonroeKM, Sotelo-TrohaK, IwigJS, EckertB, et al. (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478: 515–518.
46. SunL, WuJ, DuF, ChenX, ChenZJ (2012) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786–791.
47. AblasserA, GoldeckM, CavlarT, DeimlingT, WitteG, et al. (2013) cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498: 380–384.
48. CivrilF, DeimlingT, de Oliveira MannCC, AblasserA, MoldtM, et al. (2013) Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498: 332–337.
49. WuJ, SunL, ChenX, DuF, ShiH, et al. (2012) Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339: 826–830.
50. FennerF, AndersonDA, AritaI, JezekZ, LadnyiID (1988) Smallpox and its eradication. Geneva
51. MackettM, SmithGL, MossB (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79: 7415–7419.
52. PanicaliD, PaolettiE (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79: 4927–4931.
53. PanicaliD, DavisSW, WeinbergRL, PaolettiE (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80: 5364–5368.
54. SmithGL, MackettM, MossB (1983) Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302: 490–495.
55. SmithGL, MurphyBR, MossB (1983) Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80: 7155–7159.
56. AlcamiA, SmithGL (1996) A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93: 11029–11034.
57. CudmoreS, CossartP, GriffithsG, WayM (1995) Actin-based motility of vaccinia virus. Nature 378: 636–638.
58. DoceulV, HollinsheadM, van der LindenL, SmithGL (2010) Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327: 873–876.
59. SutterG, StaibC (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3: 263–271.
60. MeyerH, SutterG, MayrA (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 ((Pt 5)) 1031–1038.
61. BlanchardTJ, AlcamiA, AndreaP, SmithGL (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 ((Pt 5)) 1159–1167.
62. McCoyLE, FahyAS, ChenRA, SmithGL (2010) Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation. J Gen Virol 91: 2216–2220.
63. FahyAS, ClarkRH, GlydeEF, SmithGL (2008) Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89: 2377–2387.
64. GloecknerCJ, BoldtK, SchumacherA, RoepmanR, UeffingM (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7: 4228–4234.
65. KluczykA, SiemionIZ, SzewczukZ, WieczorekZ (2002) The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Peptides 23: 823–834.
66. BoskovicJ, Rivera-CalzadaA, MamanJD, ChaconP, WillisonKR, et al. (2003) Visualization of DNA-induced conformational changes in the DNA repair kinase DNA-PKcs. EMBO J 22: 5875–5882.
67. ErramiA, SmiderV, RathmellWK, HeDM, HendricksonEA, et al. (1996) Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Mol Cell Biol 16: 1519–1526.
68. BaharMW, KenyonJC, PutzMM, AbresciaNG, PeaseJE, et al. (2008) Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 4: e5.
69. NgA, TscharkeDC, ReadingPC, SmithGL (2001) The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol 82: 2095–2105.
70. AlcamiA, SmithGL (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633–4639.
71. ColamoniciOR, DomanskiP, SweitzerSM, LarnerA, BullerRM (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270: 15974–15978.
72. MossmanK, UptonC, BullerRM, McFaddenG (1995) Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208: 762–769.
73. SymonsJA, AlcamiA, SmithGL (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81: 551–560.
74. SymonsJA, TscharkeDC, PriceN, SmithGL (2002) A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J Gen Virol 83: 1953–1964.
75. MooreJB, SmithGL (1992) Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11: 1973–1980.
76. ReadingPC, MooreJB, SmithGL (2003) Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197: 1269–1278.
77. Garcia-ArriazaJ, NajeraJL, GomezCE, TewabeN, SorzanoCO, et al. (2011) A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6: e24244.
78. SumnerRP, RenH, SmithGL (2013) Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol 94: 1121–6.
79. HammarstenO, ChuG (1998) DNA-dependent protein kinase: DNA binding and activation in the absence of Ku. Proc Natl Acad Sci U S A 95: 525–530.
80. StetsonDB, KoJS, HeidmannT, MedzhitovR (2008) Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587–598.
81. KimkongI, AvihingsanonY, HirankarnN (2009) Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus 18: 1066–1072.
82. Lee-KirschMA, GongM, ChowdhuryD, SenenkoL, EngelK, et al. (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39: 1065–1067.
83. GrundyGJ, RultenSL, ZengZ, Arribas-BosacomaR, IlesN, et al. (2013) APLF promotes the assembly and activity of non-homologous end joining protein complexes. EMBO J 32: 112–125.